Drug Profile
TRX 1 - TeaRx
Alternative Names: Tearexaban; TeaRxaban; TRX1 - TeaRxLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Roche
- Developer Roche; TeaRx
- Class Anticoagulants; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Venous thromboembolism
- Discontinued Stroke
Most Recent Events
- 28 Sep 2021 TRX 1 is still in preregistration phase for Venous thromboembolism (Prevention) in Russia (TeaRx pipeline, September 2021)
- 28 Sep 2021 Discontinued - Preclinical for Stroke (Prevention) in Russia (PO) (TeaRx pipeline, September 2021)
- 14 Mar 2019 TRX 1 is still in preregistration phase for Venous thromboembolism (Prevention) in Russia (TeaRx pipeline, March 2019)